🚀 VC round data is live in beta, check it out!
Myriad Genetics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Myriad Genetics and similar public comparables like Perspective Therapeutics, Kamada, Imricor Medical Systems, Medmix and more.
Myriad Genetics Overview
About Myriad Genetics
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Founded
1992
HQ
Employees
2.7K
Website
Financials (LTM)
EV
$540M
Myriad Genetics Financials
Myriad Genetics reported last 12-month revenue of $836M and EBITDA of $38M.
In the same LTM period, Myriad Genetics generated $585M in gross profit, $38M in EBITDA, and $5M in net income.
Revenue (LTM)
Myriad Genetics P&L
In the most recent fiscal year, Myriad Genetics reported revenue of $825M and EBITDA of $39M.
Myriad Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $836M | XXX | $825M | XXX | XXX | XXX |
| Gross Profit | $585M | XXX | $577M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $38M | XXX | $39M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $5M | XXX | $6M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 1% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Myriad Genetics Stock Performance
Myriad Genetics has current market cap of $480M, and enterprise value of $540M.
Market Cap Evolution
Myriad Genetics' stock price is $5.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $540M | $480M | 0.0% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMyriad Genetics Valuation Multiples
Myriad Genetics trades at 0.6x EV/Revenue multiple, and 14.0x EV/EBITDA.
EV / Revenue (LTM)
Myriad Genetics Financial Valuation Multiples
As of April 20, 2026, Myriad Genetics has market cap of $480M and EV of $540M.
Equity research analysts estimate Myriad Genetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Myriad Genetics has a P/E ratio of 89.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $480M | XXX | $480M | XXX | XXX | XXX |
| EV (current) | $540M | XXX | $540M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 14.0x | XXX | 13.9x | XXX | XXX | XXX |
| EV/EBIT | 36.7x | XXX | 35.6x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| P/E | 89.2x | XXX | 82.7x | XXX | XXX | XXX |
| EV/FCF | (37.0x) | XXX | (39.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Myriad Genetics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Myriad Genetics Margins & Growth Rates
Myriad Genetics' revenue in the last 12 month grew by 5%.
Myriad Genetics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Myriad Genetics' rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Myriad Genetics' rule of X is 16% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Myriad Genetics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | (4%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 9% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 31% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 78% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Myriad Genetics Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Myriad Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kamada | XXX | XXX | XXX | XXX | XXX | XXX |
| Imricor Medical Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Medmix | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirxes Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Myriad Genetics M&A Activity
Myriad Genetics acquired XXX companies to date.
Last acquisition by Myriad Genetics was on XXXXXXXX, XXXXX. Myriad Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Myriad Genetics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMyriad Genetics Investment Activity
Myriad Genetics invested in XXX companies to date.
Myriad Genetics made its latest investment on XXXXXXXX, XXXXX. Myriad Genetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Myriad Genetics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Myriad Genetics
| When was Myriad Genetics founded? | Myriad Genetics was founded in 1992. |
| Where is Myriad Genetics headquartered? | Myriad Genetics is headquartered in United States. |
| How many employees does Myriad Genetics have? | As of today, Myriad Genetics has over 2K employees. |
| Who is the CEO of Myriad Genetics? | Myriad Genetics' CEO is Samraat S. Raha. |
| Is Myriad Genetics publicly listed? | Yes, Myriad Genetics is a public company listed on Nasdaq. |
| What is the stock symbol of Myriad Genetics? | Myriad Genetics trades under MYGN ticker. |
| When did Myriad Genetics go public? | Myriad Genetics went public in 1995. |
| Who are competitors of Myriad Genetics? | Myriad Genetics main competitors are Perspective Therapeutics, Kamada, Imricor Medical Systems, Medmix. |
| What is the current market cap of Myriad Genetics? | Myriad Genetics' current market cap is $480M. |
| What is the current revenue of Myriad Genetics? | Myriad Genetics' last 12 months revenue is $836M. |
| What is the current revenue growth of Myriad Genetics? | Myriad Genetics revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Myriad Genetics? | Current revenue multiple of Myriad Genetics is 0.6x. |
| Is Myriad Genetics profitable? | Yes, Myriad Genetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Myriad Genetics? | Myriad Genetics' last 12 months EBITDA is $38M. |
| What is Myriad Genetics' EBITDA margin? | Myriad Genetics' last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Myriad Genetics? | Current EBITDA multiple of Myriad Genetics is 14.0x. |
| What is the current FCF of Myriad Genetics? | Myriad Genetics' last 12 months FCF is ($15M). |
| What is Myriad Genetics' FCF margin? | Myriad Genetics' last 12 months FCF margin is (2%). |
| What is the current EV/FCF multiple of Myriad Genetics? | Current FCF multiple of Myriad Genetics is (37.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.